Rationale: Angioproliferative vasculopathy is a hallmark of pulmonary arterial hypertension
(PAH). However, little is known about how endothelial cell (EC) and smooth muscle cell …

Objectives: This study evaluated the safety and efficacy of ambrisentan for a period of 2
years in patients with pulmonary arterial hypertension (PAH). Background: Ambrisentan is …

Vascular remodeling, rather than vasoconstriction, is believed to account for high vascular
resistance in severe pulmonary arterial hypertension (PAH). We have found previously that …

This review presents and discusses a new frontier for fast, risk-free and potentially
inexpensive diagnostics of respiratory diseases by detecting volatile organic compounds …

Although obesity, dyslipidemia and insulin resistance (IR) are well known risk factors for
systemic cardiovascular disease, their impact on pulmonary arterial hypertension (PAH) is …

The WNT family of signaling proteins is essential to organ development in general and lung
morphogenesis in particular. Originally identified as a developmentally active signaling …

An increasing volume of experimental data indicates that the adventitial fibroblast, in both
the pulmonary and systemic circulations, is a critical regulator of vascular wall function in …

In the lungs, parenchymal and vascular remodelling share pathomechanisms that may
explain the relatively high prevalence (30–40%) of pulmonary hypertension (PH) in …

After the approval of bosentan for the treatment of pulmonary arterial hypertension (PAH),
European authorities required the introduction of a post-marketing surveillance system …

Pulmonary hypertension (PH) is associated with structural and mechanical changes in the
pulmonary vascular bed that increase right ventricular (RV) afterload. These changes …